Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


’Knock Off‘ Oxygen Generators A Danger For COPD Patients, Foundation Says

Online devices are not FDA approved

Executive Summary

Sub-standard supplemental oxygen devices that have flooded the market since the COVID-19 pandemic may pose a danger to patients with Chronic Obstructive Pulmonary Disease, a patient advocacy group says.

You may also be interested in...

Industry Experts Give FDA’s Pre-Cert Program Thumbs-Up

A panel of industry experts gave the US FDA’s Digital Software Precertification Program the thumbs-up during a MedCon session.

Skip Skippack COVID-19 Test, FDA Warns

The Food and Drug Administration has designated the recall of a COVID-19 test from SML Distribution LLC as class I, the US agency’s most serious classification.

Exec Chat: CEO And Founder Discusses Racial Disparities In Clinical Trials

David Maman is the CEO and founder of, a provider of video-based health monitoring tools powered by artificial intelligence. Maman shared with Medtech Insight his thoughts on the FDA’s recent guidance to increase racial and ethnic diversity in clinical trials.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts